| Name | SQ109 | CAS# | 502487-67-4 | |
|---|---|---|---|---|
| Price | ¥Inquiry/1g | Purity | 98.9% | |
| Stocking Period |
1 Day | Stock | In Stock |
| Detail
Product Information
SQ109 is a drug undergoing development for treatment of tuberculosis. SQ109 showed activity against both drug susceptible and Multi-drug-resistant tuberculosis bacteria, including Extensively drug-resistant tuberculosis strains. In preclinical studies SQ109 enhanced the activity of anti-tubercular drugs isoniazid and rifampin and reduced by >30% the time required to cure mice of experimental TB. SQ109 is being developed by OOO Infectex in Russia and by Sequella Inc internationally. I |